Phase III clinical trial for AT-877 (i.v.) in patients with acute ischemic stroke. Placebo-controlled, double-blind add-on therapy to antiplatelet drugs
Phase of Trial: Phase III
Latest Information Update: 27 Apr 2010
At a glance
- Drugs Antiplatelets; Fasudil
- Indications Embolism and thrombosis; Stroke
- Focus Therapeutic Use
- Sponsors Asahi Kasei
- 27 Apr 2010 Preliminary results suggest the primary endpoint 'Rankin scale' has not been met, according to an Asahi Kasei Pharma media release.
- 27 Apr 2010 Primary endpoint 'Rankin scale' has not been met.
- 03 Jul 2007 New trial record.